Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: Report of two cases

World Journal of Biological Psychiatry

Volumn 10, Issue 3, 2009, Pages 241-244

  Paul, Robert ^a,b   Schaaff, Nadine ^a   Padberg, Frank ^a   Möller, Hans Jürgen ^a   Frodl, Thomas ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Ketamine; NDMA antagonists; S ketamine; Treatment resistant depression

Indexed keywords

AMITRIPTYLINE; ATYPICAL ANTIPSYCHOTIC AGENT; KETAMIN RATIOPHARM; KETAMINE; KETANEST; LITHIUM; LORAZEPAM; METHYLPHENIDATE; MIRTAZAPINE; THYROID HORMONE; UNCLASSIFIED DRUG; ZIPRASIDONE; ZOPICLONE;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CARDIOVASCULAR DISEASE; CASE REPORT; CONTINUOUS INFUSION; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERABILITY; EMOTIONAL INCONTINENCE; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; INFUSION; MAJOR DEPRESSION; MALE; RACEMIC MIXTURE; RATING SCALE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HALLUCINATIONS; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; STEREOISOMERISM; TREATMENT OUTCOME;

EID: 68549092716     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970701714370     Document Type: Article

References (14)

1. Anand A, Charney DS, Oren DA, et al 2000. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 57:270-276.
2. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J 1961. An inventory for measuring depression. Arch Gen Psychiatry 4:561-571.
3. Berman RM, Cappiello A, Anand A, et al 2000. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354.
4. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP 1998. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88:82-88.
5. Crown WH, Finkelstein S, Berndt ER, et al 2002. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 63:963-971.
6. Hamilton M 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
7. Kennedy SE, Koeppe RA, Young EA, Zubieta JK 2006. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 63:1199-1208.
8. Kohrs R, Durieux ME 1998. Ketamine: Teaching an old drug new tricks. Anesth Analg 87:1186-1193.
9. Liu J, Ji XQ, Zhu XZ 2006. Comparison of psychic emergence reactions after (+/-)-ketamine and (+)-ketamine in mice. Life Sci 78:1839-1844.
10. Maeng S, Zarate CA Jr, Du J, et al. 2007. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry, Epub ahead of print.
11. Raeder JC, Stenseth LB 2000. Ketamine: A new look at an old drug. Curr Opin Anaesthesiol 13:463-468.
12. Zarate CA Jr, Singh JB, Carlson PJ, et al 2006a. A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression. Arch Gen Psychiatry 63:856-864.
13. Zarate CA Jr, Singh JB, Quiroz JA, et al 2006b. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 163:153-155.
14. Zubieta JK, Ketter TA, Bueller JA, et al 2003. Regulation of human affective responses by anterior cingulate and limbic muopioid neurotransmission. Arch Gen Psychiatry 60:1145-1153.